BioMarin Pharmaceutical | Betriebsaufwand



Operating Expenses Veränderung Datum
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
Agios Pharmaceuticals USD 135.77M 1.11B 2024-12
Alnylam Pharmaceuticals USD 698.32M 120.5M 2024-12
Amgen USD 6.78B 401M 2024-12
Bayer EUR 8.2B 5.59B 2024-12
Biogen USD 2.01B 13.3M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Gilead Sciences USD 4.43B 687M 2025-03
Incyte USD 847.73M 29.46M 2025-03
Insmed USD 334.86M 28M 2024-12
Ionis Pharmaceuticals USD 278M 59.4M 2025-03
Moderna USD 1.16B 1.06B 2025-03
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
PTC Therapeutics USD 275.66M 24.36M 2024-12
Regeneron Pharmaceuticals USD 2.44B 362M 2025-03
Roche Holding CHF 11.43B 1.48B 2024-12
Sanofi EUR 6.77B 3.75B 2024-12
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
Ultragenyx Pharmaceutical USD 287.15M 15.67M 2024-12
United Therapeutics USD 411.6M 33.4M 2025-03
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



BioMarin Pharmaceutical Betriebsaufwand - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - May 2025.